Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
Research so far says MDMA can help reduce strong anxiety symptoms in carefully run therapy studies. Most of the clinical work with MDMA has focused on post‑traumatic stress disorder (PTSD), where several trials show big improvements. There are fewer and smaller studies that test MDMA specifically for general worry or other anxiety disorders, so the evidence there is more limited. Scientists agree that the drug’s effects depend a lot on the therapy around it. Trials done in medical settings with careful screening, preparation, and follow-up report mostly favorable safety results. But studies are still small, not very diverse, and the exact brain reasons why MDMA helps are not settled. More and larger trials are needed before we know how well MDMA works for everyday anxiety or how safe it is outside tightly controlled research settings.
Researchers pooled results from 29 human studies that measured blood levels of a protein called brain-derived neurotrophic factor, or BDNF, after people received so-called psychoplastogen drugs such as ketamine or psychedelics. They found no clear change in blood BDNF after these drugs. The authors say this does not prove the…
